Your patients may have some questions about ParaGard®. To make answering them quicker
and easier, we have provided these sample frequently asked questions (FAQs) and suggested
patient-friendly answers. These FAQs are specifically designed to answer questions that our
patient Web site may generate.




Please select a question.

Could not find your question? Please use our site specific search engine to find your answer:


ParaGard® does not protect against HIV/AIDS or other sexually transmitted infections. ParaGard® must not be used by women who are or may be pregnant; have acute pelvic inflammatory disease (PID) or current behavior suggesting a high risk for PID; have had a postpregnancy or postabortion uterine infection in the past 3 months; have cancer of the uterus or cervix; have an infection in the cervix; have an allergy to any component; or have Wilson's disease. The most common side effects of ParaGard® are heavier and longer periods and spotting between periods; for most women, these typically subside after 2 to 3 months. If a woman misses her period, she must be promptly evaluated for pregnancy. Some possible serious complications that have been associated with intrauterine contraceptives, including ParaGard®, are PID, perforation of the uterus, and expulsion.

References:

  1. Data on file. Duramed Pharmaceuticals, Inc., Pomona, NY.
  2. Alvarez F, Brache V, Fernández E, et al. New insights on the mode of action of intrauterine contraceptive devices in women. Fertil Steril. 1988;49(5):768-773.
  3. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 3rd ed. Geneva, Switzerland: World Health Organization, Reproductive Health and Research; 2004.
  4. Sivin I, Stern J, Diaz S, et al. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. Am J Obstet Gynecol. 1992;166(4):1208-1213.
  5. Vessey MP, Lawless M, McPherson K, Yeates D. Fertility after stopping use of intrauterine contraceptive device.
    Br Med J. 1983;286(6359):106.
  6. Hov GG, Skjeldestad FE, Hilstad T. Use of IUD and subsequent fertility—follow-up after participation in a randomized clinical trial. Contraception. 2007;75(2):88-92.
  7. Arancibia V, Peña C, Allen HE, Lagos G. Characterization of copper in uterine fluids of patients who use the copper T-380A intrauterine device. Clin Chim Acta. 2003;332(1-2):69-78.
  8. Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzmán-Rodríguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 2001;345(8):561-567.
  9. American College of Obstetricians and Gynecologists. ACOG Educational Bulletin. Breastfeeding: maternal and infant aspects. Number 258, July 2000. Int J Gynecol Obstet. 2001;74(2):217-232.
  10. Trussell J, Leveque JA, Koenig JD, et al. The economic value of contraception: a comparison of 15 methods.
    Am J Public Health. 1995;85(4):494-503.